NEW YORK (AP) -- NeoStem's chief financial officer was named to the new position of vice president of strategic initiatives on Monday.
Two years ago, the Vatican announced an unusual partnership with NeoStem to promote the use of adult stem cells for treating disease, rather than focusing research on embryonic stem cells.
Larry May, who has long been the CFO, said he is working with incoming CFO Robert Dickey as he takes over.
Dickey most recently served as senior vice president at Hemispherx Biopharma, a company that is developing treatments for chronic fatigue syndrome and influenza. Before that, he was senior vice president, CFO and business unit manager at umbilical cord stem cell therapeutics company StemCyte
The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.